PulseExploreJournal ClubDebatesTrendingResearchersJournals
Instagram
HomeExploreJournal ClubTrending
Synapse
⌘+K
Synapse
March 3, 20260 citationsOpen Access

Immunoregulatory gene GIMAP6 suppresses lethal atherosclerotic vasculopathy and ischemic heart failure

View Full Paper
CXChen XiangNational Institute of Allergy and Infectious DiseasesKAKaja S. ArushaSwarthmore CollegeDSDanielle SpringerGovernment of the United States of America

Key Points

  • Loss of GIMAP6 leads to accelerated atherosclerosis and ischemic heart failure in the absence of hyperlipidemia.
  • Rare GIMAP6 variants are linked to severe early-onset cardiovascular disease in humans, indicating its protective role.
  • The study demonstrates the importance of immunoregulatory genes in cardiovascular risks and pathology over traditional factors.
  • Identifying GIMAP6 variants could lead to new therapeutic targets and improved management of cardiovascular risks.

Abstract

Controlling hyperlipidemia has reduced but not eliminated atherosclerotic cardiovascular disease as a predominant cause of human mortality. Here, we report that loss of the immunoregulatory gene GTPase of immunity-associated protein 6 ( GIMAP6 ), causes an inflammatory vasculopathy and accelerated atherosclerosis in the absence of hyperlipidemia. These pathologic changes in turn result in progressive cardiac ischemia, myocardial infarction, and heart failure, culminating in early death. In humans, rare deleterious GIMAP6 variants are associated with premature severe cardiovascular disease. These findings reveal GIMAP6 to play an important protective role against atherosclerotic cardiovascular disease whose identification offers opportunities for improved risk management and a target for new therapies.

Ask AI
Helpful
Bookmark
Share
View Full Paper

Cite This Study

Xiang et al. (2026) studied this question.

synapsesocial.com/papers/69a75c0cc6e9836116a246e0https://doi.org/10.64898/2026.01.26.701509
Ask AI
Helpful
Bookmark
Share
View Full Paper